Acute cardiac care & resuscitationSecondary analysis
Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial
- Secondary analysis of the DanGer Shock randomised trial
- prespecified
- sex-specific
- international
- multicentre
- open-label
Authors' conclusion
In DanGer Shock, women with STEMI-CS were older and presented later after onset of symptoms, resulting in higher mortality rates. This may have led to the apparent reduced treatment effect in women, but interaction between treatment allocation and sex was not significant, and data showing a benefit of mAFP appeared particularly in younger patients, regardless of sex.
Study context
- Population
- ST-elevation myocardial infarction (STEMI) with cardiogenic shock (STEMI-CS) excluding comatose cardiac arrest, 2013–202374 women · 281 men
- Participants
- 355 participants
- Comparison
- Microaxial flow pump (mAFP) vs standard care, by sex
- mAFPn = 179
- Standard caren = 176reference
- Primary endpoint
- All-cause mortality, by sex and randomized treatment
- Follow-up
- 180 days
Primary result
As reported in the abstract
Further findings
180-day all-cause mortality, women vs men
- Women vs men: higher mortality in women (64.9% vs 48.8%)
- P = 0.015
- women significantly older; symptom onset to randomization 2.2-fold longer in women
180-day all-cause mortality, mAFP vs standard care, patients aged ≤76 years (subgroup)
- Women (n = 41), HR
- 0.66 (0.25-1.76) (95% CI)
- Men (n = 233), HR
- 0.61 (0.40-0.92) (95% CI)
- P value for interaction = 0.92
All-cause mortality, younger patients (subgroup), long-term follow-up · up to 10 years
- Women, treatment effect HR
- 0.45 (0.19-1.09) (95% CI)
- Men, treatment effect HR
- 0.57 (0.40-0.82) (95% CI)
Original publication
Summarised from the published abstract; every number is checked against it